Here are three stocks with buy rankings and strong momentum characteristics for investors to consider on May 6th:
Three Recommended Stocks with Buy Rankings and Strong Momentum
MAIA Biotechnology, Inc. (MAIA)
This immuno-oncology company holds a Zacks Rank #1. The Zacks Consensus Estimate for its current-year earnings has increased by 44.4% over the last 60 days.
MAIA Biotechnology, Inc. Price and Consensus
MAIA Biotechnology, Inc. price-consensus-chart | MAIA Biotechnology, Inc. Quote
MAIA’s shares increased by 0.5% over the last three months, standing in contrast to the S&P 500’s decline of 5.6%. The company has a Momentum Score of A.
MAIA Biotechnology, Inc. Price
MAIA Biotechnology, Inc. price | MAIA Biotechnology, Inc. Quote
Byrna Technologies Inc. (BYRN)
This non-lethal defense technology company also ranks #1 with Zacks. The Zacks Consensus Estimate for its current-year earnings has grown nearly 25% in the past 60 days.
Byrna Technologies Inc. Price and Consensus
Byrna Technologies Inc. price-consensus-chart | Byrna Technologies Inc. Quote
Byrna’s shares surged by 33.8% over the last six months, while the S&P 500 saw a decline of 4.7%. The company possesses a Momentum Score of B.
Byrna Technologies Inc. Price
Byrna Technologies Inc. price | Byrna Technologies Inc. Quote
OncoCyte Corporation (OCX)
This precision diagnostics firm holds a Zacks Rank #1. The Zacks Consensus Estimate for its current-year earnings has risen by 39.3% over the last 60 days.
OncoCyte Corporation Price and Consensus
OncoCyte Corporation price-consensus-chart | OncoCyte Corporation Quote
OncoCyte’s shares have increased by 45.3% over the last three months, outpacing the S&P 500’s decline of 5.6%. The company also possesses a Momentum Score of B.
OncoCyte Corporation Price
OncoCyte Corporation price | OncoCyte Corporation Quote
To see a full list of top-ranked stocks, click here.
Learn more about the Momentum Score and how it is calculated here.
Stocks Likely to Experience Significant Gains
Experts have identified five stocks with the highest probability of gaining 100% or more in the upcoming months. Among these, the Director of Research highlights one stock expected to see the most substantial growth.
This leading pick is part of a rapidly growing financial firm with over 50 million customers. It offers a diverse range of innovative solutions, positioning it for significant future gains. While not all selections are successful, this stock might surpass past Zacks’ high-performing picks, like Nano-X Imaging, which increased by 129.6% in under nine months.
Free: See Our Top Stock And 4 Runners Up
OncoCyte Corporation (OCX): Free Stock Analysis Report
Byrna Technologies Inc. (BYRN): Free Stock Analysis Report
MAIA Biotechnology, Inc. (MAIA): Free Stock Analysis Report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
